The conversation is about whether it is safe to take Xeljanz, a JAK inhibitor, while also taking finasteride for hair loss. The concern is that Xeljanz weakens the immune system, which could be risky.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.